Premium
Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis
Author(s) -
Lopez Oscar L.,
Chang Yuefang,
Ives Diane G.,
Snitz Beth E.,
Fitzpatrick Annette L.,
Carlson Michelle C.,
Rapp Stephen R.,
Williamson Jeffrey D.,
Tracy Russell P.,
DeKosky Steven T.,
Kuller Lewis H.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.04.008
Subject(s) - dementia , medicine , creatinine , cognition , stroke (engine) , alzheimer's disease , disease , psychology , psychiatry , mechanical engineering , engineering
Both high or low plasma amyloid levels have been associated with risk of dementia in nondemented subjects. Methods We examined baseline plasma β‐amyloid (Aβ) levels in relationship to incident dementia during a period of 8.5 years in 2840 subjects age >75 years; 2381 were cognitively normal (CN) and 450 mild cognitive impairment. Results Increased plasma Aβ1‐40 and Aβ1‐42 levels were associated with gender (women), age, low education, creatinine levels, history of stroke, and hypertension. CN participants who developed dementia had lower levels of Aβ1‐42 and Aβ1‐42/Aβ1‐40 ratio compared with those who did not. Aβ levels did not predict dementia in mild cognitive impairment participants. Discussion There was an inverse association between Aβ1‐42 and Aβ1‐42/Aβ1‐40 ratio to risk of dementia in CN participants. Cerebral and cardiovascular disease and renal function are important determinants of increased Aβ levels and must be considered in evaluations of relationship of plasma Aβ and subsequent risk of dementia.